CryoPort (NASDAQ:CYRX) Trading Up 5.9% – What’s Next?

by · The Markets Daily

CryoPort, Inc. (NASDAQ:CYRX – Get Free Report) traded up 5.9% during trading on Tuesday . The stock traded as high as $10.04 and last traded at $10.12. 154,122 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 572,803 shares. The stock had previously closed at $9.56.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on CYRX. Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a report on Monday. UBS Group upped their target price on shares of CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a report on Wednesday, November 5th. Needham & Company LLC raised their target price on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, BTIG Research boosted their price target on CryoPort from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, CryoPort currently has a consensus rating of “Moderate Buy” and an average price target of $12.83.

Get Our Latest Analysis on CryoPort

CryoPort Stock Down 4.2%

The company has a quick ratio of 15.01, a current ratio of 15.77 and a debt-to-equity ratio of 0.40. The company has a market cap of $482.67 million, a price-to-earnings ratio of 8.24 and a beta of 1.51. The stock has a fifty day moving average price of $9.43 and a two-hundred day moving average price of $8.46.

CryoPort (NASDAQ:CYRX – Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. CryoPort had a net margin of 35.57% and a negative return on equity of 11.07%. The company had revenue of $44.23 million during the quarter, compared to analysts’ expectations of $41.22 million. As a group, sell-side analysts expect that CryoPort, Inc. will post -0.99 EPS for the current year.

Institutional Investors Weigh In On CryoPort

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jacobs Levy Equity Management Inc. boosted its stake in shares of CryoPort by 283.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company’s stock valued at $4,970,000 after buying an additional 387,440 shares during the period. PharVision Advisers LLC raised its holdings in CryoPort by 50.4% in the 3rd quarter. PharVision Advisers LLC now owns 16,498 shares of the company’s stock valued at $156,000 after acquiring an additional 5,531 shares in the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of CryoPort during the 3rd quarter valued at $285,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of CryoPort by 45.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 31,556 shares of the company’s stock valued at $299,000 after acquiring an additional 9,788 shares during the period. Finally, Mak Capital One LLC acquired a new stake in shares of CryoPort during the 3rd quarter worth $7,756,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

CryoPort Company Profile

(Get Free Report)

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

Recommended Stories